Comparison of the Quality of Oral Anticoagulant Therapy Through Patient Self-management and Management by Specialized Anticoagulation Clinics in the Netherlands: A Randomized Clinical Trial

Archives of Internal Medicine

Volumn 163, Issue 21, 2003, Pages 2639-2646

  Gadisseur, A P A ^a,b   Breukink Engbers, W G M ^c,d   Van Der Meer, F J M ^a,b   Van Den Besselaar, A M H ^a   Sturk, A ^d   Rosendaal, F R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Leiden Anticoagulation Clinic   (Netherlands)

^c Oost Gelderland Anticoagulation Clin   (Netherlands)

^d Fed of Dutch Anticoagulation Clin   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; COUMARIN ANTICOAGULANT; PHENPROCOUMON;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE CALCULATION; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HUMAN; INFORMED CONSENT; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTPATIENT DEPARTMENT; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; SELF MEDICATION; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; AMBULATORY CARE FACILITIES; ANTICOAGULANTS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NETHERLANDS; PATIENT EDUCATION; PHENPROCOUMON; PROGRAM EVALUATION; QUALITY OF HEALTH CARE; SELF CARE;

EID: 0344851886     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.21.2639     Document Type: Article

References (30)

1. Rosendaal F. The Scylla and Charybdis of oral anticoagulant treatment. N Engl J Med. 1996;335:587-589.
2. Cannegieter SC, Rosendaal FR, Wintzen A, van der Meer FJM, Vandenbroucke J, Briët E. Optimal anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
3. Hylek E, Skates S, Sheehan M, Singer D. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
4. Fihn S, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med. 1993;118:511-520.
5. Fihn S, Callahan C, Martin D, McDonell M, Henikoff J, White R. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124:970-979.
6. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med. 1993;153:1557-1562.
7. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. Lancet, 1996;348: 423-428.
8. van den Besselaar AM, van der Meer FJ, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Netherlands. Am J Clin Pathol. 1988; 90:685-690.
9. Breukink-Engbers WGM. Monitoring therapy with anticoagulants in the Netherlands. Semin Thromb Hemost. 1999;25:37-42.
10. Ansell J, Holden A, Knapic N. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. Arch Intern Med. 1989;149:2509-2511.
11. Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med. 1995;155: 2185-2189.
12. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J. 1996; 132:1095-1100.
13. Ansell JE. Empowering patients to monitor and manage oral anticoagulation therapy. JAMA. 1999;281:182-183.
14. Bernardo A. Optimizing long-term anticoagulation by patient self-management? Z Kardiol. 1998;87(suppl 4):75-81.
15. Hasenkam JM, Kimose HH, Knudsen L, et al. Self management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg. 1997; 11:935-942.
16. Hasenkam JM, Knudsen L, Kimose HH, et al. Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio. (INR) using a portable whole blood monitor: a pilot investigation. Thromb Res. 1997;85:77-82.
17. Taborski U, Muller-Berghaus G. State-of-the-art patient self-management for control of oral anticoagulation. Semin Thromb Hemost. 1999;25:43-47.
18. Sawicki PT, for the Working Group for the Study of Patient Self-management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA. 1999; 281:145-150.
19. Morsdorf S, Erdlenbruch W, Taborski U, et al. Training of patients for self-management of oral anticoagulant therapy: standards, patient suitability, and clinical aspects. Semin Thromb Hemost, 1999;25:109-115.
20. Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost. 1999;25:103-107.
21. Cromheecke M, Levi M, Colly L, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet. 2000;356:97-102.
22. van den Besselaar AMHP, Breddin K, Lutze G, et al. Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coagul Fibrinolysis. 1995;6:726-732.
23. Kapiotis S, Quehenberger P, Speiser W. Evaluation of the new method Coag-uChek for the determination of prothrombin time from capillary blood: comparison with Thrombotest on KC-1. Thromb Res. 1995;77:563-567.
24. van den Besselaar AMHP. A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin. Thromb Haemost. 2000;84:410-412.
25. Wiegman H, Vossepoel AM. A computer program for long term anticoagulation control. Comput Programs Biomed. 1977;7:71-84.
26. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost. 1996;76:12-16.
27. Rosenclaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69: 236-239.
28. Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. BrJ Haematol. 2002;117: 940-946.
29. Penning-van Beest F. Overanticoagulation on Coumarin Anticoagulant [dissertation]. Rotterdam, the Netherlands: Erasmus University; 2001:101-111.
30. Fihn SD, Gadisseur APA, Pasterkamp E, van der Meer FJM, Rosendaal FR. Comparison of variability in control of oral coumarin therapy using acenocoumarol versus phenprocoumon. Thromb Haemost. 2003;90:260-266.